항균 치료제 시장 : 약제 클래스별, 투여 경로별, 적응 질환별, 유통 채널별, 지역별
Antimicrobial Therapeutics Market, By Drug Class, By Route of Administration, By Disease Indication, By Distribution Channel, By Geography
상품코드
:
1741125
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
항균 치료제 시장은 2025년에는 1,228억 9,000만 달러로 추정되고, 2032년에는 1,799억 6,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년에 걸쳐 CAGR 5.6%를 나타낼 전망입니다.
| 보고 범위 |
보고서 세부정보 |
| 기준 연도 |
2024년 |
시장 규모(2025년) |
1,228억 9,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR : |
5.60% |
가치 예측(2032년) |
1,799억 6,000만 달러 |
항균 치료제는 사람이나 동물의 체내에서 세균을 사멸시키거나 증식하기 어렵게 하는 의약품입니다.에는 주사하거나, 혈류에 직접 주입(정맥 주사)할 수도 있습니다. 또, 크림이나 스프레이, 연고로서 피부에 바를 수도 있습니다. 그러나, 이러한 약제의 오용이나 과잉 사용에 의해 항균 치료제 내성이 출현해, 세계의 건강상의 중대한 문제가 되고 있습니다.
시장 역학 :
규제 당국의 제품 인가 증가는 예측 기간 동안 시장 성장을 가속할 것으로 전망됩니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 항균 치료제 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간 2025-2032년 시장 규모 및 연간 평균 성장률(CAGR%)을 제공합니다.
- 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안의 매트릭스에 대해 해설했습니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 파라미터에 근거해, 세계의 항균 치료제 시장 주요 기업 프로파일을 제공합니다.
- 본 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 향후 제품 발매, 유형 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
- 이 조사 보고서는 투자자, 공급업체, 제품 제조업체, 판매자, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자를 대상으로 합니다.
- 이해관계자는 세계의 항균 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- 일관된 기회 맵(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- PORTER 분석
- 합병과 인수 시나리오
제4장 항균 치료제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측의 분석
- 경제에 미치는 영향
제5장 항균 치료제 시장, 약제 클래스별(2020-2032년)
제6장 항균 치료제 시장, 투여 경로별(2020-2032년)
제7장 항균 치료제 시장, 질환별(2020-2032년)
- 호흡기 감염
- 요로 감염(UTI)
- 피부 및 연조직 감염증
- 성병(STI)
- 위장관 감염
- 중추신경계 감염
- 기타
제8장 항균 치료제 시장, 유통 채널별(2020-2032년)
제9장 항균 치료제 시장, 지역별(2020-2032년)
- 북미
- 유럽
- 영국
- 독일
- 이탈리아
- 프랑스
- 스페인
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- ASEAN
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제10장 경쟁 구도
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline plc.
- Merck & Co. Inc.
- Novartis AG
- Hoffmann-La Roche AG
- AstraZeneca plc.
- Sanofi SA
- Bayer AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences, Inc.
- AbbVie Inc.
- Allergan plc
- Mylan NV
- Alembic Pharmaceuticals Limited
제11장 섹션
KTH
영문 목차
Antimicrobial Therapeutics Market is estimated to be valued at USD 122.89 Bn in 2025 and is expected to reach USD 179.96 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 122.89 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
5.60% |
2032 Value Projection: |
USD 179.96 Bn |
Antimicrobial therapeutics are medicines that kill or make it harder for bacteria to grow and multiply in people or animals. They are often used to treat serious infections, such as pneumonia or bloodstream infections (BSIs). Antibiotics can be taken by mouth in the form of pills, tablets, or liquids. They can also be injected or given directly into the bloodstream (IV) for more severe infections. They can also be applied to the skin as a cream, spray, or ointment. When used incorrectly, antibiotics can cause serious side effects and lead to resistant microorganisms. This resistance makes it harder to treat infections with the same medicine or even other medicines that are effective against them. Antimicrobial therapeutics are medications used to treat infections caused by microorganisms, including bacteria, viruses, fungi, and parasites. These therapeutics work by either killing the microorganisms or inhibiting their growth. However, the misuse and overuse of these drugs have led to the emergence of antimicrobial resistance, which is a significant global health concern. The global antimicrobial therapeutics market is expected to grow due to the increasing prevalence of infectious diseases, the development of new drugs, and the growing awareness of antimicrobial resistance.
Market Dynamics:
Increasing product approval by regulatory bodies is expected to drive the growth of the market over the forecast period. For instance, Zydus Lifesciences, a pharmaceutical company, announced that it had received final approval from the U.S. Food and Drug Administration (FDA) to market its antifungal medicine Micafungin, which is used to treat certain types of fungal or yeast infections.
Key features of the study:
- This report provides in-depth analysis of the global antimicrobial therapeutics market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antimicrobial therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Sanofi SA, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., AbbVie Inc., Allergan plc, Mylan N.V. and Alembic Pharmaceuticals Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antimicrobial therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antimicrobial therapeutics market
Detailed Segmentation:
- Global Antimicrobial Therapeutics Market, By Drug Class:
- Antibacterials
- Antivirals
- Antifungals
- Antiparasitics
- Global Antimicrobial Therapeutics Market, By Route of Administration:
- Oral
- Topical
- Injectable
- Others
- Global Antimicrobial Therapeutics Market, By Disease Indication:
- Respiratory Infections
- Urinary Tract Infections (UTIs)
- Skin and Soft Tissue Infections
- Sexually Transmitted Infections (STIs)
- Gastrointestinal Infections
- Central Nervous System Infections
- Others
- Global Antimicrobial Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Antimicrobial Therapeutics Market, By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profile:
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- F. Hoffmann-La Roche AG
- AstraZeneca plc
- Sanofi SA
- Bayer AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences, Inc.
- AbbVie Inc.
- Allergan plc
- Mylan N.V.
- Alembic Pharmaceuticals Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Antimicrobial Therapeutics, By Drug Class
- Market Antimicrobial Therapeutics, By Route of Administration
- Market Antimicrobial Therapeutics, By Disease Indication
- Market Antimicrobial Therapeutics, By Distribution Channel
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Antimicrobial Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Antimicrobial Therapeutics Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Antibacterials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Antifungals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Antiparasitics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Antimicrobial Therapeutics Market, By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Antimicrobial Therapeutics Market, By Disease Indication, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Respiratory Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Urinary Tract Infections (UTIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Skin and Soft Tissue Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Sexually Transmitted Infections (STIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Gastrointestinal Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Central Nervous System Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Antimicrobial Therapeutics Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Antimicrobial Therapeutics Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country,2020 - 2032, (US$ Bn )
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 - 2032, (US$ Bn )
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2020 - 2032, (US$ Bn )
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
관련자료
